Interferon Alpha Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Interferon Alpha Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ — Interferon Alpha (IFNA) – Pipeline Review, H2 2016

Summary
The report provides comprehensive information on the Interferon Alpha (IFNA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889099-interferon-alpha-ifna-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape for Interferon Alpha (IFNA)
– The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects
– The report assesses Interferon Alpha (IFNA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Interferon Alpha (IFNA) Overview 6
Therapeutics Development 7
Interferon Alpha (IFNA) – Products under Development by Stage of Development 7
Interferon Alpha (IFNA) – Products under Development by Therapy Area 8
Interferon Alpha (IFNA) – Products under Development by Indication 9
Interferon Alpha (IFNA) – Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interferon Alpha (IFNA) – Products under Development by Companies 12
Interferon Alpha (IFNA) – Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Interferon Alpha (IFNA) – Companies Involved in Therapeutics Development 21
Argos Therapeutics Inc 21
Neovacs SA 22
PsiOxus Therapeutics Ltd 23
ZIOPHARM Oncology Inc 24
Interferon Alpha (IFNA) – Drug Profiles 25
AGS-009 – Drug Profile 25
Product Description 25
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889099-interferon-alpha-ifna-pipeline-review-h2-2016

Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Beijing Minhai Biotechnology Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Beijing Minhai Biotechnology Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ — Beijing Minhai Biotechnology Co Ltd – Product Pipeline Review – 2016

Summary
The report provides comprehensive information on the therapeutics under development by Beijing Minhai Biotechnology Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889100-beijing-minhai-biotechnology-co-ltd-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the pipeline therapeutic landscape of Beijing Minhai Biotechnology Co Ltd
– The report provides overview of Beijing Minhai Biotechnology Co Ltd including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses Beijing Minhai Biotechnology Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features Beijing Minhai Biotechnology Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate Beijing Minhai Biotechnology Co Ltd’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Beijing Minhai Biotechnology Co Ltd
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Beijing Minhai Biotechnology Co Ltd’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Beijing Minhai Biotechnology Co Ltd Snapshot 7
Beijing Minhai Biotechnology Co Ltd Overview 7
Key Facts 7
Beijing Minhai Biotechnology Co Ltd – Research and Development Overview 8
Key Therapeutic Areas 8
Beijing Minhai Biotechnology Co Ltd – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Pipeline Products – Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Beijing Minhai Biotechnology Co Ltd – Pipeline Products Glance 16
Beijing Minhai Biotechnology Co Ltd – Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Beijing Minhai Biotechnology Co Ltd – Clinical Stage Pipeline Products 18
Phase I Products/Combination Treatment Modalities 18
Beijing Minhai Biotechnology Co Ltd – Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889100-beijing-minhai-biotechnology-co-ltd-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

BioLingus AG Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

BioLingus AG – Product Pipeline Review – 2016

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ — BioLingus AG – Product Pipeline Review – 2016

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889101-biolingus-ag-product-pipeline-review-2016

Summary
The report provides comprehensive information on the therapeutics under development by BioLingus AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the pipeline therapeutic landscape of BioLingus AG
– The report provides overview of BioLingus AG including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses BioLingus AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features BioLingus AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate BioLingus AG’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for BioLingus AG
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding BioLingus AG’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
BioLingus AG Snapshot 6
BioLingus AG Overview 6
Key Facts 6
BioLingus AG – Research and Development Overview 7
Key Therapeutic Areas 7
BioLingus AG – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
BioLingus AG – Pipeline Products Glance 11
BioLingus AG – Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
BioLingus AG – Unknown Stage Pipeline Products 13
Unknown Products/Combination Treatment Modalities 13
BioLingus AG – Drug Profiles 14
aldesleukin – Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
Cellular Immunotherapy to Target Survivin for Oncology – Drug Profile 15
Product Description 15
Mechanism Of Action 15
R&D Progress 15
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889101-biolingus-ag-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Hydrocephalus Market: Industry Analysis, Demand, Trend and Global Forecast to 2022

Hydrocephalus Market Information, by category, diagnosis type, treatment type and by region type – Forecast to 2022

Key Players: HLL Life care Limited, ChristophMiethke GmbH & Co. KG, Codman &Shurtleff, Inc., DePuySynthes Companies, HP BioprotesesLtda.”

— Market Research Future

PUNE, MAHARASHTRA , INDIA , January 19, 2017 /EINPresswire.com/ — Market Research Future published a half – cooked research report on Hydrocephalus Market. The global market is expected to grow over the CAGR of around 10% during the period 2016 to 2021.

Market Highlights:
The Hydrocephalus Market has been a growing market and it has been expected that the market will touch high growth figures. The demand for surgical procedures due to the increasing cases of the condition is expected to drive the devices and medications market for hydrocephalus.

Taste the market data and market information presented through more than 40 market data tables and figures spread over 60 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Hydrocephalus Market Research Report: Global Forecast to 2022”.

Hydrocephalus Market:
On the basis of diagnosis type the Market on the basis of hydrocephalus category the market is segmented as congenital, compensated, acquired and others. On the basis of diagnosis type the market is segmented as head ultrasound, CT scan – head and others. On the basis of treatment type the market is segmented as surgery – shunt insertion, medication and others.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1719

Market Research Analysis:
Hydrocephalus market has an important quotient in the growth of pharmaceutical and life science market. Hydrocephalus is one of the most common birth defects, each year one out of every 500 births results in this condition. In the coming years, it is expected that the market will advance with higher growth rate as compared to previous years. The current challenges for the market are the medications segment which needs a lot of research and clinical trials for effective results over treatment of this condition.

Segments:
Hydrocephalus Market on the basis of category the market is segmented as congenital, compensated, acquired and others. On the basis of diagnosis type the market is segmented as head ultrasound, CT scan – head and others. On the basis of treatment type the market is segmented as surgery – shunt insertion, medication and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/hydrocephalus-market

Brief TOC for Hydrocephalus Market:
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4 Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 PORTERS Five Forces
5.3 Demand & Supply: gap analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
5.7 Upcoming trends in market
Continue…

Intended Audience:
• Research and Development (R&D) Companies
• Government Research Laboratories
• Independent Research Laboratories
• Government and Independent Regulatory Authorities
• Market Research and Consulting Service Providers
• Medical Research Laboratories
• Academic Medical Institutes and Universities

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

Biomar Microbial Technologies Market 2017 Share, Trend, Segmentation and Forecast to 2020


Wise.Guy12

Wise.Guy.

Biomar Microbial Technologies – Product Pipeline Review – 2016

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ — Biomar Microbial Technologies – Product Pipeline Review – 2016

Summary
The report provides comprehensive information on the therapeutics under development by Biomar Microbial Technologies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889102-biomar-microbial-technologies-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the pipeline therapeutic landscape of Biomar Microbial Technologies
– The report provides overview of Biomar Microbial Technologies including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses Biomar Microbial Technologies’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features Biomar Microbial Technologies’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate Biomar Microbial Technologies’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Biomar Microbial Technologies
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Biomar Microbial Technologies’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Biomar Microbial Technologies Snapshot 7
Biomar Microbial Technologies Overview 7
Key Facts 7
Biomar Microbial Technologies – Research and Development Overview 8
Key Therapeutic Areas 8
Biomar Microbial Technologies – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Biomar Microbial Technologies – Pipeline Products Glance 13
Biomar Microbial Technologies – Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Biomar Microbial Technologies – Drug Profiles 15
IB-05202 – Drug Profile 15
Product Description 15
Mechanism Of Action 15
R&D Progress 15
IB-06202 – Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
IB-07A037 – Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
IB-07A081 – Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889102-biomar-microbial-technologies-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Idaho Mesothelioma Victims Center Now Urges a Power Plant Worker with Mesothelioma in Idaho To Call Them About the Compensation Process and Attorneys Who Get the Best Financial Results

As we would like discuss anytime at 800-714-0303 you need experienced, national caliber mesothelioma attorneys if you want to get the best mesothelioma compensation for a diagnosed person in Idaho

— Idaho Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, January 19, 2017 /EINPresswire.com/ — The Idaho Mesothelioma Victims Center says, "One of the things we specialize in is helping power or energy workers who have been diagnosed with mesothelioma get the best possible financial compensation. If we had a vital piece of advice it would be, “Please think out of the box when it comes to hiring a lawyer to assist with a mesothelioma compensation claim involving a power or energy worker in Idaho.

"As we would like discuss anytime at 800-714-0303 you need experienced, national caliber mesothelioma attorneys if you want to get the best possible mesothelioma compensation for a diagnosed person in Idaho." http://Idaho.MesotheliomaVictimsCenter.Com

The Center's focus is making certain a person with mesothelioma in Idaho receives the very best financial compensation for this extremely rare form of cancer caused by asbestos exposure. Power and energy make everything in Idaho work and as the Center would like to explain anytime at 800-714-0303 these types of victims of mesothelioma are not exclusive to Idaho. They are in fact nationwide-so are the fulltime mesothelioma attorneys who help these types of people with this asbestos exposure form of cancer. http://Idaho.MesotheliomaVictimsCenter.Com

Vital Mesothelioma Compensation Tip for a diagnosed person in Idaho or their family members: “Think big when it comes to mesothelioma compensation if we are talking about a power or energy worker in Idaho with this rare cancer. There really are top mesothelioma attorneys who specialize in helping these types of people or their family get the best financial compensation. Why settle for less-or a lot less?" http://Idaho.MesotheliomaVictimsCenter.Com

For the best possible mesothelioma treatment options in Idaho the Idaho Mesothelioma Victims Center strongly recommends the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital: St. Luke’s Mountain States Tumor Institute Boise, Idaho: https://www.saintlukeshealthsystem.org/services/cancer-care

The Idaho Mesothelioma Victims Center’s unsurpassed services are available to a diagnosed person anywhere in Idaho including communities such as Boise, Nampa, Meridian, Idaho Falls, Pocatello, Coeur d’Alene, Twin Falls, Wallace, or Lewiston.

High risk work groups for exposure to asbestos in Idaho include US Navy Veterans, miners, power plant workers, manufacturing workers, smelter workers, pulp or paper mill workers, military base workers, carpenters, plumbers, electricians, auto mechanics, machinists, or construction workers. In most instances these types of people were exposed to asbestos in the 1950’s, 1960’s, 1970’s, or 1980’s. http://Idaho.MesotheliomaVictimsCenter.Com

The states with the highest incidence of mesothelioma include Pennsylvania, Massachusetts, Maine, New Jersey, West Virginia, Florida, Wyoming, and Washington. However, mesothelioma does happen in Idaho as the Idaho Mesothelioma Victims Center would like to explain anytime at 800-714-0303.

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Michael Thomas
Idaho Mesothelioma Victims Center
800-714-0303
email us here


Source: EIN Presswire

Lasik Eye Surgery Market is expected to grow at USD 1.6 billion by 2022: Vendors- Abbott Inc., Alcon and Carl Zeiss

Lasik Eye Surgery Market is expected to grow at USD 1.6 billion by 2022: Vendors- Abbott Inc., Alcon and Carl Zeiss

Key Players – AMO Manufacturing USA LLC, Nidek, Inc., Abbott Inc., Alcon Laboratories, Inc., Carl Zeiss, Inc., Bausch & Lomb Surgical, Inc., Lasersight Technologies, Inc. ”

— Market Research Future

PUNE, MAHARASTRA, INDIA, January 19, 2017 /EINPresswire.com/ — Market Scenario

The global market for LASIK eye surgery is expected to grow by 6.7% CAGR during the period 2016 to 2022 from USD 1.6 billion in 2022.

LASIK Eye Surgery Market has been evaluated as rapidly growing market and expected that the market will reach high growth figures in the near future. There has been a tremendous growth in the number of people opting for corrective eye surgery. Huge numbers of women are opting for the LASIK eye surgery in order to get rid of eye glasses and to avoid the headache of maintaining contact lenses. Refractive errors are the most common cases in the vision problems which can be very efficiently corrected using LASIK eye surgery.

Request for Sample Report@ https://www.marketresearchfuture.com/sample_request/1774

Key Player

AMO Manufacturing USA LLC
Nidek, Inc.
Abbott Inc.
Alcon Laboratories, Inc.
Carl Zeiss, Inc.
Bausch & Lomb Surgical, Inc.
Lasersight Technologies, Inc.
Segmentation

LASIK eye surgery market has been segmented on the basis of types which comprises of wavefront optimized, wavefront-guided, topography guided and all laser. On the basis of vision error, market is segmented into myopia, hyperopia, astigmatism and others. On the basis of end user, market is segmented into hospital, eye care clinic, LASIK center and others.

Test the market data and market information presented through more than 50 market data tables and figures spread over 85 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “LASIK Eye Surgery Market Research Report –Global Forecast to 2022.”

Regional Analysis

Globally North America is the largest market for LASIK Eye Surgery Market. Europe is the second-largest market. Furthermore Asia pacific market is expected to be the fastest growing market for LASIK eye surgery.

Browse Full Research Report @ https://www.marketresearchfuture.com/reports/lasik-eye-surgery-market

TOC of Lasik Eye Surgery Market

1 Introduction

2 Research Methodologies

3 Market Dynamics

4 Market Factor Analysis

5 Global Lasik Eye Surgery Market, By Types

6 Global Lasik Eye Surgery Market, By Vision Error

7 Global Lasik Eye Surgery Market, By End User

8 Global Lasik Eye Surgery Market, By Region

9 Competitive Landscapes

10 Company Profile

Continued……

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com

Web: https://www.marketresearchfuture.com

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

Polyphor Ltd. Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Polyphor Ltd. Treatment Pipeline Review H2 2017

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ — Polyphor Ltd – Product Pipeline Review – 2016
Summary
The report provides comprehensive information on the therapeutics under development by Polyphor Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889103-polyphor-ltd-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the pipeline therapeutic landscape of Polyphor Ltd
– The report provides overview of Polyphor Ltd including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses Polyphor Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features Polyphor Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate Polyphor Ltd’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Polyphor Ltd
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Polyphor Ltd’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Polyphor Ltd Snapshot 6
Polyphor Ltd Overview 6
Key Facts 6
Polyphor Ltd – Research and Development Overview 7
Key Therapeutic Areas 7
Polyphor Ltd – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Polyphor Ltd – Pipeline Products Glance 14
Polyphor Ltd – Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Polyphor Ltd – Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Polyphor Ltd – Drug Profiles 18
balixafortide – Drug Profile 18
Product Description 18
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889103-polyphor-ltd-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global ENT Navigation Systems Market 2017 Share, Trend, Segmentation and Forecast to 2021

ENT Navigation Systems -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021

PUNE , MAHARASHTRA, INDIA, January 19, 2017 /EINPresswire.com/ — ENT Navigation Systems Industry

Description

Wiseguyreports.Com Adds “ENT Navigation Systems -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

This report studies sales (consumption) of ENT Navigation Systems in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering

Medtronic
Brainlab
Stryker
Renishaw
Mazor Robotics
Intuitive Surgical
TransEnterix
Accuray
Hansen Medical
Corindus
Catheter Precision
Stereotaxis

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/876585-global-ent-navigation-systems-sales-market-report-2017

Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of ENT Navigation Systems in these regions, from 2011 to 2021 (forecast), like

United States
China
Europe
Japan
Southeast Asia
India

Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into
Autonomous instruments
Traditional steel tools

Split by applications, this report focuses on sales, market share and growth rate of ENT Navigation Systems in each application, can be divided into
Surgical
Industrial

Leave a Query @ https://www.wiseguyreports.com/enquiry/876585-global-ent-navigation-systems-sales-market-report-2017

Table of Contents

Global ENT Navigation Systems Sales Market Report 2017
1 ENT Navigation Systems Overview
1.1 Product Overview and Scope of ENT Navigation Systems
1.2 Classification of ENT Navigation Systems
1.2.1 Autonomous instruments
1.2.2 Traditional steel tools
1.3 Application of ENT Navigation Systems
1.3.1 Surgical
1.3.2 Industrial
1.4 ENT Navigation Systems Market by Regions
1.4.1 United States Status and Prospect (2011-2021)
1.4.2 China Status and Prospect (2011-2021)
1.4.3 Europe Status and Prospect (2011-2021)
1.4.4 Japan Status and Prospect (2011-2021)
1.4.5 Southeast Asia Status and Prospect (2011-2021)
1.4.6 India Status and Prospect (2011-2021)
1.5 Global Market Size (Value and Volume) of ENT Navigation Systems (2011-2021)
1.5.1 Global ENT Navigation Systems Sales and Growth Rate (2011-2021)
1.5.2 Global ENT Navigation Systems Revenue and Growth Rate (2011-2021)

9 Global ENT Navigation Systems Manufacturers Analysis
9.1 Medtronic
9.1.1 Company Basic Information, Manufacturing Base and Competitors
9.1.2 ENT Navigation Systems Product Type, Application and Specification
9.1.2.1 Autonomous instruments
9.1.2.2 Traditional steel tools
9.1.3 Medtronic ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.1.4 Main Business/Business Overview
9.2 Brainlab
9.2.1 Company Basic Information, Manufacturing Base and Competitors
9.2.2 ENT Navigation Systems Product Type, Application and Specification
9.2.2.1 Autonomous instruments
9.2.2.2 Traditional steel tools
9.2.3 Brainlab ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.2.4 Main Business/Business Overview
9.3 Stryker
9.3.1 Company Basic Information, Manufacturing Base and Competitors
9.3.2 ENT Navigation Systems Product Type, Application and Specification
9.3.2.1 Autonomous instruments
9.3.2.2 Traditional steel tools
9.3.3 Stryker ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.3.4 Main Business/Business Overview
9.4 Renishaw
9.4.1 Company Basic Information, Manufacturing Base and Competitors
9.4.2 ENT Navigation Systems Product Type, Application and Specification
9.4.2.1 Autonomous instruments
9.4.2.2 Traditional steel tools
9.4.3 Renishaw ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.4.4 Main Business/Business Overview
9.5 Mazor Robotics
9.5.1 Company Basic Information, Manufacturing Base and Competitors
9.5.2 ENT Navigation Systems Product Type, Application and Specification
9.5.2.1 Autonomous instruments
9.5.2.2 Traditional steel tools
9.5.3 Mazor Robotics ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.5.4 Main Business/Business Overview
9.6 Intuitive Surgical
9.6.1 Company Basic Information, Manufacturing Base and Competitors
9.6.2 ENT Navigation Systems Product Type, Application and Specification
9.6.2.1 Autonomous instruments
9.6.2.2 Traditional steel tools
9.6.3 Intuitive Surgical ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.6.4 Main Business/Business Overview
9.7 TransEnterix
9.7.1 Company Basic Information, Manufacturing Base and Competitors
9.7.2 ENT Navigation Systems Product Type, Application and Specification
9.7.2.1 Autonomous instruments
9.7.2.2 Traditional steel tools
9.7.3 TransEnterix ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.7.4 Main Business/Business Overview
9.8 Accuray
9.8.1 Company Basic Information, Manufacturing Base and Competitors
9.8.2 ENT Navigation Systems Product Type, Application and Specification
9.8.2.1 Autonomous instruments
9.8.2.2 Traditional steel tools
9.8.3 Accuray ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.8.4 Main Business/Business Overview
9.9 Hansen Medical
9.9.1 Company Basic Information, Manufacturing Base and Competitors
9.9.2 ENT Navigation Systems Product Type, Application and Specification
9.9.2.1 Autonomous instruments
9.9.2.2 Traditional steel tools
9.9.3 Hansen Medical ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.9.4 Main Business/Business Overview
9.10 Corindus
9.10.1 Company Basic Information, Manufacturing Base and Competitors
9.10.2 ENT Navigation Systems Product Type, Application and Specification
9.10.2.1 Autonomous instruments
9.10.2.2 Traditional steel tools
9.10.3 Corindus ENT Navigation Systems Sales, Revenue, Price and Gross Margin (2011-2016)
9.10.4 Main Business/Business Overview
9.11 Catheter Precision
9.12 Stereotaxis

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=876585

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Symphogen A/S Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Symphogen A/S Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, January 19, 2017 /EINPresswire.com/ — Symphogen A/S – Product Pipeline Review – 2016

Summary
The report provides comprehensive information on the therapeutics under development by Symphogen A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889104-symphogen-a-s-product-pipeline-review-2016

Scope
– The report provides a snapshot of the pipeline therapeutic landscape of Symphogen A/S
– The report provides overview of Symphogen A/S including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses Symphogen A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features Symphogen A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate Symphogen A/S’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Symphogen A/S
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Symphogen A/S’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Symphogen A/S Snapshot 6
Symphogen A/S Overview 6
Key Facts 6
Symphogen A/S – Research and Development Overview 7
Key Therapeutic Areas 7
Symphogen A/S – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
Symphogen A/S – Pipeline Products Glance 12
Symphogen A/S – Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Symphogen A/S – Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889104-symphogen-a-s-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire